Regeneron Pharmaceuticals Inc. on Wednesday said it intendsto file by mid-1992 an investigational new drug application tobegin clinical trials of CNTF.
In remarks to analysts at a meeting held by EGS Partners, aNew York investment fund, Dr. Leonard Schleifer, president andchief executive officer, said ciliary neurotrophic factor wouldbe tested for treatment of amyotrophic lateral sclerosis. Thedrug is one of several neurotrophic factors under developmentat the Tarrytown, N.Y., company.
Regeneron stock (NASDAQ:REGN) gained 75 cents, closing at$18.25.
(c) 1997 American Health Consultants. All rights reserved.